Last reviewed · How we verify
Angiotensin receptor blocker
Angiotensin receptor blockers block the angiotensin II type 1 receptor, preventing vasoconstriction and aldosterone release to lower blood pressure.
Angiotensin receptor blockers block the angiotensin II type 1 receptor, preventing vasoconstriction and aldosterone release to lower blood pressure. Used for Hypertension, Heart failure with reduced ejection fraction, Diabetic nephropathy.
At a glance
| Generic name | Angiotensin receptor blocker |
|---|---|
| Also known as | Candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan, Losartan |
| Sponsor | National University of Ireland, Galway, Ireland |
| Drug class | Angiotensin receptor blocker |
| Target | AT1 receptor (Angiotensin II type 1 receptor) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
ARBs selectively antagonize the AT1 receptor on vascular smooth muscle and adrenal tissue, blocking the effects of angiotensin II. This prevents vasoconstriction, reduces aldosterone-mediated sodium and water retention, and decreases sympathetic nervous system activation. The result is reduced peripheral vascular resistance and lower blood pressure.
Approved indications
- Hypertension
- Heart failure with reduced ejection fraction
- Diabetic nephropathy
- Post-myocardial infarction
Common side effects
- Dizziness
- Fatigue
- Hyperkalemia
- Cough
- Hypotension
Key clinical trials
- Efficacy and Safety of Sacubitril/Valsartan in African American Patients With Heart Failure With Reduced Ejection Fraction
- A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria (PHASE3)
- The GUARDIAN Pilot Trial (NA)
- Focusing on the Menopausal Transition to Improve Mid-Life Women's Health (PHASE2, PHASE3)
- A Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Treatment With AP1189 in Patients With iMN and Severe Proteinuria (PHASE2)
- Vascular Intervention Strategies Trial for Alzheimer's (PHASE2)
- Exercise Rehabilitation for Cardiorenal Syndrome in HFrEF Patients (NA)
- Immune System in Diabetic Kidney Disease
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: